Shuffler News
Parkinsons and Dopamine Agonists, a story !
The words of someone who has been to hell and back and still climbing out of it.
“Agonists are like your best friend acting nice, but in the bigger picture they have an alterior motive far more sinister than any benefit that the friendship could ever provide.
For most it works, but my experience was stomach churningly horrendous, with life long repucussions of the highest order, loss of business, reputation, family houses, economic and social supports.
Structured social and medical supports, as well as paitent suitability given patient personailty and lifestyle, are required that extend way beyond what the medical profession currently offers .
These supports need to look for and continually monitor for the hidden signals, behaviour changes, reclusiveness, adverse risk taking, clouded judgement, as the participant can very easily deliberately hide the obvious signs of compulsive behaviour, which may seem trivial to those looking in, but will rock the foundations for the person who sought the benefit, ripping their insides with decay and leaving a shell of a human with nothing left inside.”
There is a moral duty of care that isn’t being acknowledged, and those affected are too proud to publicly admit that they fell prey to the fiery forks of the devil disguised.
This could never happen to me, I won’t be judged by my friends so I’ll keep it to myself”
Stories from Agonist Survivors
Parkinsons: Dopamine Agonists. Dangers !
While Spending Thanksgiving Apart, I’ll Hold My Sister in My Heart
It’s the time of year when many of us relish connecting with our families and friends and spending time together to reflect on our blessings. I’m talking about Thanksgiving, of course, although sometimes it feels
New Engagement Council Seeks Patient Insight for Treatment R&D
Aiming to improve the clinical outcomes of people with Parkinson’s disease, pharmaceutical company UCB is partnering with key U.K. and U.S. nonprofits to establish the Patient Engagement Council for Parkinson’s Research. UCB is teaming up
Age at Disease Onset Results in Distinct Speech Patterns
People with early- or late-onset Parkinson’s disease tend to have different characteristic changes in their speech, according to a new study. The study, “Distinct patterns of speech disorder in early-onset and late-onset de-novo Parkinson’s disease,” was
Cala Health Raises $77M for Bioelectronic Devices for Tremors
Cala Health has raised $77 million that will support further innovations of the company’s expertise — bioelectronic medicine — to explore conditions beyond essential tremor, including Parkinson’s disease and other neurological conditions. The funding also will
‘Yours, Truly’ Campaign Focuses on Non-motor Symptoms
To heighten awareness and understanding of non-motor Parkinson’s disease symptoms such as hallucinations and delusions, Acadia Pharmaceuticals and StoryCorps have teamed up to open Yours, Truly, a multicultural storytelling campaign. The national effort, which also seeks
Swedish Researchers Develop Tools to Manage Care More Effectively
A Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and treat patients with Parkinson’s disease. The group, led by Per Odin, MD, PhD, professor at
1st Trial of Anesthetic Ketamine for Depression in Parkinson’s Wins $2M
Two scientists at Yale University were awarded $2 million from the Michael J. Fox Foundation to conduct the first clinical trial investigating the use of ketamine — a powerful anesthetic — as a treatment for
Meditation Helps Me Seek the Quiet Mind
The “pause between” is my new Parkinson’s self-management tool. I use it every day to help me switch from old ways of reacting to the “flicker effect” (dysregulated systems). It provides improved threshold management and
STAR Molecule to Restore GCase Activity Showing Early Potential
An oral candidate therapy for Parkinson’s disease called GT-02287 lowered the levels of alpha-synuclein accumulation and inflammation, and lessened behavioral deficits in animal models of the disease. “We are working diligently to advance this breakthrough compound to
Phase 2 Trial Planned for KM-819 as Disease-modifying Therapy
Fascinate Therapeutics plans to launch a Phase 2 clinical trial into the safety and early efficacy of KM-819 as a potential therapy for Parkinson’s disease. This follows the approval by the U.S. Food and Drug Administration of
Posts from the author
Shufflernews
Parkinsons
Subscribe
Phone
0490 33 22 68
shuffles@shufflenews.com